Nathalie Couque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nathalie Couque has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Lyse Ruaud
Département de génétique, hôpital Robert-Debré, Paris, France
4 shared publications - Jacques Elion
Laboratoire d’Excellence GR-Ex, UMR_S1134, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Institut National de la Transfusion Sanguine, 75015 Paris, France
3 shared publications - Alain Verloes
Dept of Genetics, Assistance Publique-Hôpitaux de Paris, Université de Paris, Robert DEBRE University Hospital, Paris, France
2 shared publications - Jonathan Levy
Department of Genetics, APHP-Robert Debré University Hospital, Paris, France
2 shared publications - Valentine Brousse
Centre de Référence MCGRE, Service d'Hématologie‐Immunologie, AP‐HP Hôpital Robert Debré Paris France
2 shared publications - Yline Capri
Service de Génétique Clinique, Robert-Debré Hospital Nord-Université Paris Cité
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (45)
Comprehensive classification of HCN1 variants linked to neurodevelopmental disorders with and without epilepsy
Hyperpolarization-activated cyclic nucleotide-gated 1 (HCN1) channels mediate the cationic I h current, a fundamental regulator of neuronal excitability and synaptic integration, and are predominantly expressed in the cortex and hippocampus. Although HCN1 variants have been increasingly identified in patients with epilepsy, from milder forms to developmental and epileptic encephalopathies (DEE), genotype–phenotype correlations remain poorly defined. Here, we used patch-clamp electrophysiology and confocal imaging in HEK293 cells to functionally characterize 43 HCN1 variants identified in patients with neurodevelopmental disorders, with or without epilepsy. Based on biophysical properties, we established a classification system comprising four distinct functional classes: I) low or no current; II) hyperpolarizing shift in voltage dependence; III) depolarizing shift in voltage dependence; and IV) generation of an instantaneous current. The molecular basis for this classification was further interpreted using available cryo-EM structures of HCN1. Integration with clinical data from 50 patients revealed a striking correlation between functional class and clinical presentation. Loss-of-function variants prevailed among individuals with milder phenotypes or without epilepsy, with the latter distinctively clustering within the channel selectivity filter. In contrast, gain-of-function and mixed variants were predominantly associated with DEE. Finally, we demonstrate that allosteric modulators, including peptides NB6 and TRIP8b nano and the small molecule J&J12e, effectively normalize channel function across three of the four classes in vitro. These findings establish a biophysical framework for interpreting HCN1 variants, demonstrating that the direction of channel dysfunction is a major determinant of epilepsy risk and severity, and providing a conceptual foundation for future class-based precision medicine approaches.
- 4 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (45)
Open AccessComprehensive classification of HCN1 variants linked to neurodevelopmental disorders with and without epilepsy
Hyperpolarization-activated cyclic nucleotide-gated 1 (HCN1) channels mediate the cationic I h current, a fundamental regulator of neuronal excitability and synaptic integration, and are predominantly expressed in the cortex and hippocampus. Although HCN1 variants have been increasingly identified in patients with epilepsy, from milder forms to developmental and epileptic encephalopathies (DEE), genotype–phenotype correlations remain poorly defined. Here, we used patch-clamp electrophysiology and confocal imaging in HEK293 cells to functionally characterize 43 HCN1 variants identified in patients with neurodevelopmental disorders, with or without epilepsy. Based on biophysical properties, we established a classification system comprising four distinct functional classes: I) low or no current; II) hyperpolarizing shift in voltage dependence; III) depolarizing shift in voltage dependence; and IV) generation of an instantaneous current. The molecular basis for this classification was further interpreted using available cryo-EM structures of HCN1. Integration with clinical data from 50 patients revealed a striking correlation between functional class and clinical presentation. Loss-of-function variants prevailed among individuals with milder phenotypes or without epilepsy, with the latter distinctively clustering within the channel selectivity filter. In contrast, gain-of-function and mixed variants were predominantly associated with DEE. Finally, we demonstrate that allosteric modulators, including peptides NB6 and TRIP8b nano and the small molecule J&J12e, effectively normalize channel function across three of the four classes in vitro. These findings establish a biophysical framework for interpreting HCN1 variants, demonstrating that the direction of channel dysfunction is a major determinant of epilepsy risk and severity, and providing a conceptual foundation for future class-based precision medicine approaches.
- Open Access
- 6 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1856-1865
Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia
Summary: Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP. Median age at diagnosis was 4.9 years [3.6–6.1], with median follow‐up of 13.3 years (915 patient‐years). Transcranial Doppler (TCD) velocities and magnetic resonance angiography (MRA) normalised in 35 patients, that is, they had reversal of CV (RCV group). Fifteen patients had no reversal of CV (No‐RCV group). Kaplan–Meier analysis estimated that 48% (95% confidence interval [CI] [33–62]) still had abnormal TCD and/or MRA 5 years after diagnosis. In a multivariate Cox model, three baseline factors independently predicted CV reversal: age at CV onset, initial severity of stenosis and bronchial obstruction. Older age at diagnosis increased the likelihood of CV reversal (hazard ratio [HR] 1.31 per year, 95% CI [1.08–1.59], p = 0.01). In contrast, severe stenosis (HR 0.72 per 10% increase, 95% CI [0.62–0.85], p < 0.0001) and bronchial obstruction (HR 0.14, 95% CI [0.03–0.63], p = 0.001) reduced the likelihood of CV reversal. These results suggest that, beyond TP, managing bronchial obstruction may improve vascular outcomes.
- 6 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1856-1865
Open AccessIdentification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia
Summary: Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP. Median age at diagnosis was 4.9 years [3.6–6.1], with median follow‐up of 13.3 years (915 patient‐years). Transcranial Doppler (TCD) velocities and magnetic resonance angiography (MRA) normalised in 35 patients, that is, they had reversal of CV (RCV group). Fifteen patients had no reversal of CV (No‐RCV group). Kaplan–Meier analysis estimated that 48% (95% confidence interval [CI] [33–62]) still had abnormal TCD and/or MRA 5 years after diagnosis. In a multivariate Cox model, three baseline factors independently predicted CV reversal: age at CV onset, initial severity of stenosis and bronchial obstruction. Older age at diagnosis increased the likelihood of CV reversal (hazard ratio [HR] 1.31 per year, 95% CI [1.08–1.59], p = 0.01). In contrast, severe stenosis (HR 0.72 per 10% increase, 95% CI [0.62–0.85], p < 0.0001) and bronchial obstruction (HR 0.14, 95% CI [0.03–0.63], p = 0.001) reduced the likelihood of CV reversal. These results suggest that, beyond TP, managing bronchial obstruction may improve vascular outcomes.
- Open Access
- 3 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (18)
Mutations in the spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly
The spliceosome is a critical cellular machinery responsible for pre-mRNA splicing that is essential for the proper expression of genes. Mutations in its core components are increasingly linked to neurodevelopmental disorders, such as primary microcephaly. Here, we investigated the role of SNW domain–containing protein 1 (SNW1), a spliceosomal protein, in splicing integrity and neurodevelopment. We identified 9 heterozygous mutations in the SNW1 gene in patients presenting with primary microcephaly. These mutations impaired SNW1’s interactions with core spliceosomal proteins, leading to defective RNA splicing and reduced protein functionality. Using Drosophila melanogaster and human embryonic stem cell–derived cerebral organoids models, we demonstrated that SNW1 depletion resulted in significant reductions in neural stem cell proliferation and increased apoptosis. RNA-Seq revealed disrupted alternative splicing, especially skipping exons, and altered expression of neurodevelopment-associated genes ( CENPE , MEF2C , and NRXN2 ). Our findings provide crucial insights into the molecular mechanisms by which SNW1 dysfunction contributes to neurodevelopmental disorders and underscore the importance of proper spliceosome function in brain development.
- 3 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (18)
Open AccessMutations in the spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly
The spliceosome is a critical cellular machinery responsible for pre-mRNA splicing that is essential for the proper expression of genes. Mutations in its core components are increasingly linked to neurodevelopmental disorders, such as primary microcephaly. Here, we investigated the role of SNW domain–containing protein 1 (SNW1), a spliceosomal protein, in splicing integrity and neurodevelopment. We identified 9 heterozygous mutations in the SNW1 gene in patients presenting with primary microcephaly. These mutations impaired SNW1’s interactions with core spliceosomal proteins, leading to defective RNA splicing and reduced protein functionality. Using Drosophila melanogaster and human embryonic stem cell–derived cerebral organoids models, we demonstrated that SNW1 depletion resulted in significant reductions in neural stem cell proliferation and increased apoptosis. RNA-Seq revealed disrupted alternative splicing, especially skipping exons, and altered expression of neurodevelopment-associated genes ( CENPE , MEF2C , and NRXN2 ). Our findings provide crucial insights into the molecular mechanisms by which SNW1 dysfunction contributes to neurodevelopmental disorders and underscore the importance of proper spliceosome function in brain development.
- Open Access
- 9 November 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (3)
A second RUBCN variant associated with epileptic encephalopathy and neurodevelopmental delay
The RUBCN gene encodes a widely expressed protein called Rubicon, the main function of which is to negatively regulate macroautophagy. A single homozygous pathogenic variant of the RUBCN gene has been reported to date in two unrelated consanguineous Saudi families with spinocerebellar ataxia autosomal recessive 15 (OMIM#613516). This variant is responsible for the deletion of the highly conserved Rubicon Homology (RH) domain, which is important for the colocalization of Rubicon with Rab7 in the late endosome. In this work, we describe a female patient with childhood‐onset epileptic encephalopathy and neurodevelopmental delay carrying a novel homozygous variant in RUBCN (NM_014687.3: c.2126 + 1G>A). A functional study of the RNA revealed that this variant completely abolishes the consensus donor site at the exon 14/intron 14 junction, resulting in the absence of expression of the reference transcript. Two alternative transcripts were expressed: a major transcript resulting from activation of an alternative exonic splice site and a minor transcript with skipping of exon 14. The two alternative transcripts lead to a shift in the reading frame introducing a premature stop codon. The resulting truncated protein lacks the RH domain, which may lead to defective endosomal trafficking as previously described. To our best knowledge, this is the first report of an impairment of RUBCN caused by a splice variant.
- 9 November 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (3)
Open AccessA second RUBCN variant associated with epileptic encephalopathy and neurodevelopmental delay
The RUBCN gene encodes a widely expressed protein called Rubicon, the main function of which is to negatively regulate macroautophagy. A single homozygous pathogenic variant of the RUBCN gene has been reported to date in two unrelated consanguineous Saudi families with spinocerebellar ataxia autosomal recessive 15 (OMIM#613516). This variant is responsible for the deletion of the highly conserved Rubicon Homology (RH) domain, which is important for the colocalization of Rubicon with Rab7 in the late endosome. In this work, we describe a female patient with childhood‐onset epileptic encephalopathy and neurodevelopmental delay carrying a novel homozygous variant in RUBCN (NM_014687.3: c.2126 + 1G>A). A functional study of the RNA revealed that this variant completely abolishes the consensus donor site at the exon 14/intron 14 junction, resulting in the absence of expression of the reference transcript. Two alternative transcripts were expressed: a major transcript resulting from activation of an alternative exonic splice site and a minor transcript with skipping of exon 14. The two alternative transcripts lead to a shift in the reading frame introducing a premature stop codon. The resulting truncated protein lacks the RH domain, which may lead to defective endosomal trafficking as previously described. To our best knowledge, this is the first report of an impairment of RUBCN caused by a splice variant.
- 10 September 2024
- Published by Elsevier in Archives de Pédiatrie
- Vol. 31 (7) , 470-472
A new nonsense pathogenic variant in exon 1 of PHOX2B leads to the diagnosis of congenital central hypoventilation syndrome with intra-familial variability
- 10 September 2024
- Published by Elsevier in Archives de Pédiatrie
- Vol. 31 (7) , 470-472
A new nonsense pathogenic variant in exon 1 of PHOX2B leads to the diagnosis of congenital central hypoventilation syndrome with intra-familial variability
- Open Access
- 10 February 2024
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 68, 104923
Beyond 'speech delay': Expanding the phenotype of BRPF1-related disorder
- 10 February 2024
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 68, 104923
Open AccessBeyond 'speech delay': Expanding the phenotype of BRPF1-related disorder
- Open Access
Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature
SETD2 belongs to the family of histone methyltransferase proteins and has been associated with three nosologically distinct entities with different clinical and molecular features: Luscan–Lumish syndrome (LLS), intellectual developmental disorder, autosomal dominant 70 (MRD70), and Rabin–Pappas syndrome (RAPAS). LLS [MIM #616831] is an overgrowth disorder with multisystem involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay. RAPAS [MIM #6201551] is a recently reported multisystemic disorder characterized by severely impaired global and intellectual development, hypotonia, feeding difficulties with failure to thrive, microcephaly, and dysmorphic facial features. Other neurologic findings may include seizures, hearing loss, ophthalmologic defects, and brain imaging abnormalities. There is variable involvement of other organ systems, including skeletal, genitourinary, cardiac, and potentially endocrine. Three patients who carried the missense variant p.Arg1740Gln in SETD2 were reported with a moderately impaired intellectual disability, speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. Due to the differences with the two previous phenotypes, this association was then named intellectual developmental disorder, autosomal dominant 70 [MIM 620157]. These three disorders seem to be allelic and are caused either by loss-of-function, gain-of-function, or missense variants in the SETD2 gene. Here we describe 18 new patients with variants in SETD2, most of them with the LLS phenotype, and reviewed 33 additional patients with variants in SETD2 that have been previously reported in the scientific literature. This article offers an expansion of the number of reported individuals with LLS and highlights the clinical features and the similarities and differences among the three phenotypes associated with SETD2.
Open AccessClinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature
SETD2 belongs to the family of histone methyltransferase proteins and has been associated with three nosologically distinct entities with different clinical and molecular features: Luscan–Lumish syndrome (LLS), intellectual developmental disorder, autosomal dominant 70 (MRD70), and Rabin–Pappas syndrome (RAPAS). LLS [MIM #616831] is an overgrowth disorder with multisystem involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay. RAPAS [MIM #6201551] is a recently reported multisystemic disorder characterized by severely impaired global and intellectual development, hypotonia, feeding difficulties with failure to thrive, microcephaly, and dysmorphic facial features. Other neurologic findings may include seizures, hearing loss, ophthalmologic defects, and brain imaging abnormalities. There is variable involvement of other organ systems, including skeletal, genitourinary, cardiac, and potentially endocrine. Three patients who carried the missense variant p.Arg1740Gln in SETD2 were reported with a moderately impaired intellectual disability, speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. Due to the differences with the two previous phenotypes, this association was then named intellectual developmental disorder, autosomal dominant 70 [MIM 620157]. These three disorders seem to be allelic and are caused either by loss-of-function, gain-of-function, or missense variants in the SETD2 gene. Here we describe 18 new patients with variants in SETD2, most of them with the LLS phenotype, and reviewed 33 additional patients with variants in SETD2 that have been previously reported in the scientific literature. This article offers an expansion of the number of reported individuals with LLS and highlights the clinical features and the similarities and differences among the three phenotypes associated with SETD2.
- 27 June 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (4) , 396-404
EPHA7 haploinsufficiency is associated with a neurodevelopmental disorder
Ephrin receptor and their ligands, the ephrins, are widely expressed in the developing brain. They are implicated in several developmental processes that are crucial for brain development. Deletions in genes encoding for members of the Eph/ephrin receptor family were reported in several neurodevelopmental disorders. The ephrin receptor A7 gene (EPHA7) encodes a member of ephrin receptor subfamily of the protein‐tyrosine kinase family. EPHA7 plays a role in corticogenesis processes, determines brain size and shape, and is involved in development of the central nervous system. One patient only was reported so far with a de novo deletion encompassing EPHA7 in 6q16.1. We report 12 additional patients from nine unrelated pedigrees with similar deletions. The deletions were inherited in nine out of 12 patients, suggesting variable expressivity and incomplete penetrance. Four patients had tiny deletions involving only EPHA7, suggesting a critical role of EPHA7 in a neurodevelopmental disability phenotype. We provide further evidence for EPHA7 deletion as a risk factor for neurodevelopmental disorder and delineate its clinical phenotype.
- 27 June 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (4) , 396-404
EPHA7 haploinsufficiency is associated with a neurodevelopmental disorder
Ephrin receptor and their ligands, the ephrins, are widely expressed in the developing brain. They are implicated in several developmental processes that are crucial for brain development. Deletions in genes encoding for members of the Eph/ephrin receptor family were reported in several neurodevelopmental disorders. The ephrin receptor A7 gene (EPHA7) encodes a member of ephrin receptor subfamily of the protein‐tyrosine kinase family. EPHA7 plays a role in corticogenesis processes, determines brain size and shape, and is involved in development of the central nervous system. One patient only was reported so far with a de novo deletion encompassing EPHA7 in 6q16.1. We report 12 additional patients from nine unrelated pedigrees with similar deletions. The deletions were inherited in nine out of 12 patients, suggesting variable expressivity and incomplete penetrance. Four patients had tiny deletions involving only EPHA7, suggesting a critical role of EPHA7 in a neurodevelopmental disability phenotype. We provide further evidence for EPHA7 deletion as a risk factor for neurodevelopmental disorder and delineate its clinical phenotype.
- 1 December 2019
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 40, A103
L’arthrite au cours de la sarcoïdose aiguë et chronique : caractéristiques et traitement. Étude française rétrospective multicentrique
- 1 December 2019
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 40, A103
L’arthrite au cours de la sarcoïdose aiguë et chronique : caractéristiques et traitement. Étude française rétrospective multicentrique
- Open Access
- 2 October 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (10) , 1594
Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France
This study’s objective was to assess, on a national scale, residual risks of death, major disease-related events, and quality of care during the first five years in children diagnosed at birth with sickle cell disease (SCD). Data were retrospectively collected from medical files of all children with SCD born between 2006–2010 in France. Out of 1792 eligible subjects, 1620 patients (71.8% SS or S/beta°-thalassemia -SB°-) had available follow-up data, across 69 centers. Overall probability of survival by five years was 98.9%, with 12/18 deaths related to SCD. Probability of overt stroke by five years in SS/SB° patients was 1.1%, while transcranial Doppler (TCD) was performed in 81% before three years of age. A total of 26 patients had meningitis/septicemia (pneumococcal in eight cases). Prophylactic penicillin was started at a median age of 2.2 months and 87% of children had received appropriate conjugate pneumococcal vaccination at one year. By five years, the probability of survival without SCD-related events was 10.7% for SS/SB° patients. In contrast, hydroxyurea was prescribed in 13.7% and bone marrow transplant performed in nine patients only. In this study, residual risks of severe complications were low, probably resulting from a good national TCD, vaccination, and healthcare system coverage. Nonetheless, burden of disease remained high, stressing the need for disease-modifying or curative therapy.
- 2 October 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (10) , 1594
Open AccessEvaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France
This study’s objective was to assess, on a national scale, residual risks of death, major disease-related events, and quality of care during the first five years in children diagnosed at birth with sickle cell disease (SCD). Data were retrospectively collected from medical files of all children with SCD born between 2006–2010 in France. Out of 1792 eligible subjects, 1620 patients (71.8% SS or S/beta°-thalassemia -SB°-) had available follow-up data, across 69 centers. Overall probability of survival by five years was 98.9%, with 12/18 deaths related to SCD. Probability of overt stroke by five years in SS/SB° patients was 1.1%, while transcranial Doppler (TCD) was performed in 81% before three years of age. A total of 26 patients had meningitis/septicemia (pneumococcal in eight cases). Prophylactic penicillin was started at a median age of 2.2 months and 87% of children had received appropriate conjugate pneumococcal vaccination at one year. By five years, the probability of survival without SCD-related events was 10.7% for SS/SB° patients. In contrast, hydroxyurea was prescribed in 13.7% and bone marrow transplant performed in nine patients only. In this study, residual risks of severe complications were low, probably resulting from a good national TCD, vaccination, and healthcare system coverage. Nonetheless, burden of disease remained high, stressing the need for disease-modifying or curative therapy.